Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ALKS 58.27 +1.97 (3.50%)
price chart
Alkermes plc Reports First Quarter 2017 Financial Results
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Analyst Activity – Cowen and Company Reiterates Buy on Alkermes Plc (NASDAQ ...  Market Exclusive
Zacks: Analysts Anticipate Alkermes Plc (ALKS) Will Announce Quarterly Sales ...  Sports Perspectives
Alkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript
Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today.
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2016 and ...  Business Wire (press release)
Why Alkermes PLC Skyrocketed Today
Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.
Credit Suisse Bullish on Alkermes Plc (ALKS) as It Takes a Leap FORWARD  Smarter Analyst
Alkermes Surge by a Record 47% on Depression Pill Trial Success  Bloomberg
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward
Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.
Alkermes plc (ALKS) LT Estimates Cut At Morgan Stanley Citing Ampyra Patent ...
Morgan Stanley maintains Equalweight on Alkermes (NASDAQ: ALKS) price target of $62.00. Analyst David Risinger assumes Ampyra generics could hit the market in 2018 as opposed to prior expectations of 2027.
Alkermes plc (ALKS): One Step Forward, One Back - Jefferies
Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Alkermes (NASDAQ: ALKS) along with his price target of $70, after IP rulings on Ampyra and Tecfidera proved to be a net neutral event.
Analyst Activity – Jefferies Group LLC Reiterates Buy on Alkermes Plc ...  Market Exclusive
Alkermes plc (ALKS) Closed the Last Trading Session at $58.5  The Newburgh Press
Investors Are Missing An Opportunity With Alkermes
We remain bullish on Alkermes (NASDAQ: ALKS) because of their substantial and growing revenue and their healthy pipeline of valuable assets.
Alkermes plc (ALKS) to Present Data on Two-Month Dosing Option of ARISTADA at ...
Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA� (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress ...
Analyst Activity – Morgan Stanley Reiterates Equal Weight on Alkermes Plc ...
Today, Morgan Stanley reiterated its Equal Weight rating on Alkermes Plc (NASDAQ:ALKS) with a price target of $62.00. There are 3 hold ratings, 7 buy ratings on the stock.
FY2018 Earnings Estimate for Alkermes Plc (ALKS) Issued By Leerink Swann  The Cerbat Gem
EPS for Alkermes Plc (ALKS) Expected At $-0.24; New Mountain Vantage ...  HuronReport
Trading Options: Alkermes plc (NASDAQ:ALKS) : Using Covered Calls to ...
While covered calls are one of the most commonly used option strategies, it turns out we need to be clever in how we treat earnings in order to maximize the strategy in Alkermes plc (NASDAQ:ALKS) . Even further, if we don't do this analysis, we can ...